Bioxytran (BIXT) Return on Capital Employed (2011 - 2026)
Bioxytran (BIXT) posted Return on Capital Employed of 74.55% for Q1 2026, up 15.02% sequentially from 64.82% in Q4 2025, and up 218.0% YoY from 23.44% in Q1 2025.
Bioxytran (BIXT) Return on Capital Employed (2011 - 2026) Analysis & Trends
Bioxytran has reported Return on Capital Employed for 16 years, with the latest figure at 74.55% in Q1 2026.
- Quarterly Return on Capital Employed rose 218.0% year-over-year to 74.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 74.55% (up 218.0% YoY) and the FY2025 annual result came in at 64.62%, down 5946.0% from the prior year.
- Return on Capital Employed improved to 74.55% in Q1 2026 per BIXT's latest filing, from 64.82% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 389.37% in Q1 2024 and troughed at 59.25% in Q3 2025.
- A 5-year average of 128.12% and a median of 75.61% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 33005 bps in 2024, then tumbled 31699 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 74.78% in 2022, then soared by 65 bps to 123.38% in 2023, then gained by 1 bps to 124.77% in 2024, then tumbled by 48 bps to 64.82% in 2025, then increased by 15 bps to 74.55% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 74.55%, 64.82%, and 59.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 76.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.55% |
| Dec 31, 2025 | 64.82% |
| Sep 30, 2025 | 59.25% |
| Jun 30, 2025 | 59.59% |
| Mar 31, 2025 | 72.37% |
| Dec 31, 2024 | 124.77% |
| Sep 30, 2024 | 249.28% |
| Jun 30, 2024 | 306.94% |
| Mar 31, 2024 | 389.37% |
| Dec 31, 2023 | 123.38% |
| Sep 30, 2023 | 179.42% |
| Jun 30, 2023 | 111.90% |
| Mar 31, 2023 | 59.31% |
| Dec 31, 2022 | 74.78% |
| Sep 30, 2022 | 91.52% |
| Jun 30, 2022 | 61.19% |
| Mar 31, 2022 | 75.61% |
| Dec 31, 2021 | 148.57% |
| Sep 30, 2021 | 219.77% |
| Jun 30, 2021 | 231.01% |